City Therapeutics arrives on Nasdaq with $200 million to push RNAi deeper into the clinic
City Therapeutics has gone public with an upsized $200 million IPO, a financing that gives the Cambridge, Massachusetts company fresh capital to carry a cluster of RNA interference programs through early development and into later-stage testing. Shares are set to begin trading on the Nasdaq under the ticker CTY, and the offering lands at a moment when investor appetite for RNAi companies has returned after a long stretch in which the modality waited for broader market validation.
The deal priced in the middle of its anticipated range at $18 a share, above the lower end of the company’s expected funding plan and above the net proceeds City had previously suggested. Underwriters also have an option to buy an additional 1.7 million shares, which could add roughly $30 million more if fully exercised. For a young biotech, that is not just balance-sheet relief. It is the difference between keeping multiple clinical paths alive and being forced to narrow the portfolio before the science has had a fair test.
City has organized its lead capital plan around three programs, each aimed at a different therapeutic problem but built on the same RNAi engineering logic. The company has already set aside $30 million to fund CITY-FXI, a Factor XI-targeting RNAi therapeutic, through an ongoing phase 1 study and into a mid-stage trial in patients who have undergone knee surgery, a setting where thrombosis is common. It has earmarked another $20 million for CITY-RBP4, a GalNAc-conjugated siRNA being advanced through phase 1 with plans to evaluate it in Stargardt disease and geographic atrophy. A further $40 million is reserved for CITY-TFR2, another GalNAc-conjugated candidate that is due to enter a trial in China later this year as a potential treatment for anemia.
The lead program is the most clinically intuitive. Factor XI has become one of the most closely watched coagulation targets in drug development because it sits at the intersection of thrombosis prevention and bleeding risk reduction. In a postoperative setting such as knee surgery, clot formation is a predictable hazard, yet conventional anticoagulation can exact a price in bleeding. An RNAi strategy aimed at lowering Factor XI production offers a mechanistically attractive route to blunt thrombosis while preserving more hemostatic reserve than older anticoagulants. The choice of the knee surgery population reflects that logic with unusual clarity: the event burden is high enough to measure, and the medical need is immediate enough to justify aggressive development.
One sentence captures the company’s strategy better than any financing slide: City is not building a single asset; it is testing whether RNAi can become a platform for multiple chronic diseases.
The same platform thinking appears in the retinal program. CITY-RBP4 uses GalNAc conjugation, a delivery approach designed to improve uptake in hepatocytes and sharpen target engagement for liver-mediated diseases. The company’s near-term plan is to move through phase 1 before exploring retinal indications such as Stargardt disease and geographic atrophy, two conditions that continue to create substantial unmet need in inherited and degenerative eye disease. For retinal medicine, the attraction of a systemic RNAi approach is the possibility of altering disease biology upstream rather than repeatedly chasing downstream damage after vision has already been lost.
Anemia may prove to be the broadest commercial and clinical test of City’s platform. CITY-TFR2 is slated for a trial in China later this year and is being positioned as a treatment for anemia, with future expansion plans into chronic kidney disease and inflammatory diseases, including inflammatory bowel disease. Those settings matter because anemia is rarely a standalone diagnosis in chronic illness; it is often a marker of inflammation, impaired iron handling, renal dysfunction, or a mix of all three. A therapeutic approach that can modulate iron homeostasis or erythropoiesis through a durable RNAi mechanism could, if successful, find a place across several chronic care pathways.
The company enters public markets with an RNAi pedigree that remains unusually strong for a young biotech. City was launched in 2024 with backing from pioneers associated with Alnylam Pharmaceuticals, including John Maraganore, Ph.D., Mark Keating, M.D., and Tracy Zimmermann, Ph.D. When City raised its $99.5 million series B in June, CEO Andy Orth framed RNAi drugs as a class with the potential to change medicine in much the same way antibodies once did. That comparison is more than a fundraising slogan. Antibodies succeeded because they converted biologic specificity into reproducible clinical action, and RNAi aims to do something similar at the level of gene silencing.
Partnerships with Bausch + Lomb and Biogen already give the company external validation beyond the public markets. They also suggest that larger industry players continue to see RNAi as more than a narrow niche technology. In practical terms, those collaborations can help de-risk development, deepen translational expertise and widen the set of indications that can be pursued without turning every program into a stand-alone commercial bet.
City’s market debut also arrives soon after another RNA-focused biotech, ADARx Pharmaceuticals, completed a $446.3 million public listing. That offering has held up since launch, a sign that investors are willing to back the broader modality again after years in which only the strongest stories could command serious capital. Even so, the financing environment remains selective. Public markets are rewarding platforms that can tie biology to a clear disease setting, a tractable path through early development and a reasonable explanation for how the mechanism should translate into patient benefit.
Frazier Life Sciences also reached the Nasdaq on the same day with its second biotech-focused special purpose acquisition company, raising about $75 million through the sale of 7.5 million shares at $10 apiece. The SPAC, led by Albert Cha, M.D., Ph.D., is designed to identify a biotech candidate for a reverse merger. Its arrival reflects a partial revival of a financing structure that once dominated the sector and then cooled sharply after 2022. A handful of recent examples have shown that the route has not disappeared, but it no longer carries the momentum it once did.
City now has public capital, several programs with distinct biological rationales and enough runway to move from early human testing into more clinically meaningful studies. The next inflection point will not come from the IPO itself. It will come from whether the company can turn RNAi’s theoretical precision into data that hold up in thrombosis, retinal disease and anemia—three settings where mechanism alone will not be enough.